Jeil Pharmaceutical제일약품
271980 · KOSPI · ₩271980 · 제일약품
₩8,830▲ ₩30 (0.34%)End-of-day · Oct 28, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩567B | ₩705B | ₩726B | ₩722B | ₩701B |
| Cost of sales | ₩354B | ₩527B | ₩542B | ₩565B | ₩545B |
| Gross profit | ₩213B | ₩177B | ₩184B | ₩157B | ₩156B |
| Operating income | ₩21B | −₩19B | ₩8.7B | −₩14B | −₩11B |
| Net income | ₩32B | −₩30B | ₩5.2B | −₩15B | −₩15B |
| Net income to shareholders | ₩23B | −₩30B | ₩5B | −₩13B | −₩12B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩511B | ₩526B | ₩487B | ₩457B | ₩426B |
| Current assets | ₩312B | ₩343B | ₩317B | ₩292B | ₩285B |
| Cash and equivalents | ₩49B | ₩53B | ₩33B | ₩31B | ₩26B |
| Total liabilities | ₩260B | ₩306B | ₩330B | ₩301B | ₩259B |
| Current liabilities | ₩242B | ₩292B | ₩318B | ₩269B | ₩222B |
| Borrowings | ₩90B | ₩71B | ₩65B | ₩43B | ₩32B |
| Total equity | ₩251B | ₩219B | ₩157B | ₩156B | ₩167B |
| Shareholders' equity | ₩211B | ₩188B | ₩159B | ₩158B | ₩168B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩5.7B | ₩3.2B | −₩5B | −₩15B | ₩19B |
| Capital spending | ₩8B | ₩4.3B | ₩6.1B | ₩11B | ₩5.3B |
| Free cash flow | −₩14B | −₩1.1B | −₩11B | −₩26B | ₩14B |
| Dividends paid | ₩0 | ₩728M | ₩728M | ₩948M | ₩1B |
Consolidated where available. Amounts in won.
Also known as: Jeil Pharmaceutical / 제일약품 / 271980 / KRX:271980
Source: KRX statistical information